| 2.35 0.065 (2.84%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.17 | 1-year : | 3.57 |
| Resists | First : | 2.72 | Second : | 3.06 |
| Pivot price | 2.83 |
|||
| Supports | First : | 2.16 | Second : | 1.8 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 2.81 |
| MA(100) : | 3.31 |
MA(250) : | 3.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.6 |
D(3) : | 58.1 |
| RSI | RSI(14): 33.6 |
|||
| 52-week | High : | 4.7 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ORGO ] has closed below the lower bollinger band by 6.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ORGO ] is to continue within current trading range. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.39 - 2.4 | 2.4 - 2.41 |
| Low: | 2.23 - 2.25 | 2.25 - 2.26 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Thu, 25 Apr 2024
Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference - The Globe and Mail
Thu, 11 Apr 2024
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Has Been Sliding But Fundamentals Look Strong: Is The ... - Yahoo Movies Canada
Wed, 10 Apr 2024
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt? - Simply Wall St
Sat, 02 Mar 2024
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 29 Feb 2024
Organogenesis: Q4 Earnings Snapshot - Quartz
Thu, 29 Feb 2024
Organogenesis Holdings Inc (ORGO) Faces Revenue Decline in Q4 and FY 2023, Aims for Growth in 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 132 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 33.3 (%) |
| Held by Institutions | 44.9 (%) |
| Shares Short | 7,230 (K) |
| Shares Short P.Month | 7,570 (K) |
| EPS | 0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 1.1 % |
| Operating Margin | 0.6 % |
| Return on Assets (ttm) | 2.2 % |
| Return on Equity (ttm) | 1.8 % |
| Qtrly Rev. Growth | -13.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.28 |
| EBITDA (p.s.) | 0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 31 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | 58.75 |
| PEG Ratio | -118.7 |
| Price to Book value | 1.1 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 10.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|